Citizens JMP Reiterates Market Outperform Rating on Context Therapeutics (CNTX)

Citizens JMP analyst Silvan Tuerkcan reiterated a Market Outperform rating and $4.00 price target on Context Therapeutics (NASDAQ: CNTX).

The analyst commented, "As Context Therapeutics moves its second asset into the clinic in 2Q25, the company issued full-year financial results. Context ended 2024 with $94.4M in cash and cash equivalents, and had FY opex of $29.9M, which is expected to fund operations through two interim clinical readouts and into 2027. We maintain our Market Outperform rating and $4 DCF-derived price target… CNTX is an early-stage company that selected several bispecific TCE antibodies based on key aspects to overcome TCE limitations. Current programs have relied on learnings in both target [antigen] biology and bispecific TCE drug development to develop assets with optimized characteristics. By this time next year we should expect to see the first data set from CTIM-76 in CLDN6-positive ovarian, endometrial, and testicular cancers, two areas of need."

For an analyst ratings summary and ratings history on Context Therapeutics click here. For more ratings news on Context Therapeutics click here.

Shares of Context Therapeutics closed at $0.77 yesterday.

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results